Patrick J. Medina, PharmD, BCOP, is Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa.
Nivolumab versus Cabozantinib: Second-Line Therapy for Metastatic Renal-Cell Carcinoma Still Unresolved
As options for second-line therapy for patients with metastatic renal-cell carcinoma continue to expand, so does the controversy surrounding optimal treatment selection.
As pharmacists’ responsibilities extend beyond dispensing medications to include advanced patient-centered services, many already meet the definition of nonphysician provider under Medicare Part B, yet they are often not reimbursed for their services.
Although beneficence, autonomy, and justice comprise the bulwark of ethical principles in medicine, their prioritization has changed over the course of history.
The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer.
Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality.
Despite significant progress in stem-cell transplantations over the past decade, graft-versus-host disease (GVHD) remains the leading cause of nonrelapse death in this patient population.
Precision medicine continues to transform oncology, and it is not just the treatments that are changing.
According to the results of a recent survey of hematopoietic stem-cell transplantation (HSCT) professionals, burnout is prevalent across all HSCT disciplines, with pharmacists showing the highest rates of burnout and moral distress.
The overtreatment or undertreatment of patients with cancer can have life-or-death implications.